DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20163695

Addition of immunotherapy to chemotherapy in pediatric borderline leprosy: a clinical evaluation

Raj Kamal, Natrajan M., Dayal R.

Abstract


Background:Immunotherapy with BCG, BCG + M. leprae, ICRC, MIP has been observed to be effective in improving the treatment in adulthood leprosy. Clinical improvement with accelerated bacterial clearance and histological up grading using MIP vaccine as an immunotherapeutic with standard WHO-MDT has been reported in adult cases with high bacillary load. However, there is lack of information in borderline pediatric leprosy which is characterized by a state of shifting immunity and would therefore be ideally suited to such observations. This pilot study is originated from involvement of our Institute in a trial aimed for improving the therapy of pediatric borderline leprosy by using combined immunotherapy and chemotherapy. The study was aimed to assess the clinical improvement by adding immunotherapy (MIP vaccine) with chemotherapy (WHO -MDT) in pediatric borderline leprosy.

Methods: A total of 98 new pediatric borderline leprosy cases were included, after formal written consent, detailed clinical examination. A non-randomized trial was conducted. In this study, patients attending the OPD were serially recruited in two treatment groups. In group-1 (Mw vaccine plus WHO- MDT) 50 pediatric cases and in Group-2 (MDT only), 48 pediatric borderline cases were recruited. The therapeutic regimens containing MIP vaccine was injected intra-dermally at the start of therapy and every six months in addition to chemotherapy (WHO- MDT) in group 1 pediatric patient and chemotherapy only (WHO- MDT) were given in group-2 pediatric cases and effect was observed on clinical parameters (size of lesions, erythema, infiltration, sensory improvement) and bacillary clearance.

Results:Addition of immunotherapy resulted in faster clinical recovery from disease, faster bacillary clearance in pediatric borderline leprosy cases.

Conclusions:This study shows the usefulness of adding immunotherapy (MIP vaccine) to chemotherapy (WHO- MDT) in pediatric borderline leprosy for faster clinical improvement.


Keywords


Chemotherapy, Immunotherapy, Leprosy, MIP vaccine, WHO-MDT, Pediatric borderline

Full Text:

PDF

References


Convit J, Aranzazu N and Ulrich M (1982). Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda negative contacts. Int J Lepr. 1982;50:415-24.

Bhatki WS, Chulawala RG. The immunothera-peutic potential of ICRC vaccine a case-controlled study. Lepr Rev. 1992;63:358-64.

Kar HK, Sharma AK, Mishra RS. Reversal reactions in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate anti-leprosy vaccine mycobacterium. Lepr Rev. 1993;64:219-26.

Talwar GP. An immunotherapeutic vaccine for multibacillary leprosy. Int Rev Immunol. 1999;18:229-49.

Natrajan M, Katoch K, Bagga AK. Histological changes in combined chemotherapy and immunotherapy in highly bacillated lepromatous leprosy. Acta Leprol. 1992;8:79-86.

Sharma P, Mishra RS, Kar HK. Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy a report on hospital-based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment. Lepr Rev. 2000;71:179-92.

Katoch K, Katoch VM, Natrajan M. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy. Vaccine. 2014;22:3649-57.

Ridley DS. Histological classification and the immunological spectrum of leprosy. Bull WHO. 1974;51:451-65.

Kamal R, Katoch K, Natrajan M, Arora M. Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy Ind J Lepr. 2012;84:287-306.

Narang T, Kaur I, Kumar B. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy. Int J Lepr. 2005;73:105-14.

Kaplan G, Britton WJ, Hancock GE. The systemic effect of recombinant interleukin-2 on the manifestations of lepromatous leprosy. J Exp Med. 1991;173:993-1006.

Zaheer SA, Mukherjee R, Beena KR. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis. 1993;167:401-10.

Sarkar AD, Kaur I, Radotra BD. Impact of combined mycobacterium w vaccine and 1 year of MDT on multibacillary leprosy patients. Int J Lepr. 2001;60:187-94.